{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:08:31Z","timestamp":1764601711281,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clml.2020.05.009","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T03:12:10Z","timestamp":1590030730000},"page":"652-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Comparison of the BEAM and MITO\/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9580-628X","authenticated-orcid":false,"given":"Mahmut","family":"Yeral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-1565","authenticated-orcid":false,"given":"Pelin","family":"Aytan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burcu","family":"Gungor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"Boga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Unal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yener","family":"Koc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leylagul","family":"Kaynar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurhilal","family":"Buyukkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bulent","family":"Eser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Ozdo\u011fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.05.009_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1056\/NEJM199302253280808","article-title":"Hodgkin's disease","volume":"328","author":"DeVita","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.009_bib2","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.05.009_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.05.009_bib4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/annonc\/mdi248","article-title":"High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study","volume":"16","author":"Josting","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.05.009_bib5","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1634\/theoncologist.2009-0162","article-title":"Controversies in the treatment of lymphoma with autologous transplantation","volume":"14","author":"Moskowitz","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.05.009_bib6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/bmt.2015.6","article-title":"Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015","volume":"50","author":"Sureda","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.009_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/2193-1801-2-489","article-title":"Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS","volume":"2","author":"Sharma","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.clml.2020.05.009_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/bmt.2015.273","article-title":"Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT","volume":"51","author":"Sellner","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.bmt.1705744","article-title":"Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?","volume":"40","author":"Fernandez","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.009_bib12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1080\/10428190600570958","article-title":"High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed\/refractory lymphoma","volume":"47","author":"Oyan","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.05.009_bib13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored international working group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.009_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"year":"2009","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","key":"10.1016\/j.clml.2020.05.009_bib15"},{"key":"10.1016\/j.clml.2020.05.009_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bmt.1702154","article-title":"Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies","volume":"25","author":"Alessandrino","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A\u00a0SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.05.009_bib18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/bmt.2012.282","article-title":"Suggestions on the use of statistical methodologies in studies of the European group for blood and marrow transplantation","volume":"48","author":"Iacobelli","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2012.10.029","article-title":"Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome","volume":"19","author":"Nieto","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.bbmt.2019.01.032","article-title":"BEAM versus BUCYVP16 conditioning before autologous hematopoietic stem cell transplant in patients with Hodgkin lymphoma","volume":"25","author":"Singer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib21","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","article-title":"Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1702795","article-title":"Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens","volume":"27","author":"Salar","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/bjc.1997.465","article-title":"High-dose mitoxantrone with peripheral blood progenitor cell rescue:toxicity, pharmacokinetics and implications for dosage and schedule","volume":"76","author":"Ballestrero","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2020.05.009_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.1994.12.1.141","article-title":"Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation","volume":"12","author":"Attal","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.009_bib25","first-page":"490","article-title":"The role of mitoxantrone in non-Hodgkin's lymphoma","volume":"16","author":"Armitage","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2020.05.009_bib26","first-page":"210","article-title":"A\u00a0phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma","volume":"3","author":"Schenkein","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.leu.2402011","article-title":"High-dose mitoxantrone\u00a0+ melphalan (MITO\/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity","volume":"15","author":"Tarella","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.009_bib28","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2020.05.009_bib29","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Martinez","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.05.009_bib30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","article-title":"Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma","volume":"12","author":"Majhail","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2020.05.009_bib31","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1080\/10428194.2016.1185785","article-title":"Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning","volume":"57","author":"Isidori","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.05.009_bib32","series-title":"The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies","first-page":"653","article-title":"Classical Hodgkin\u2019s lymphoma","author":"Sureda","year":"2019"},{"key":"10.1016\/j.clml.2020.05.009_bib33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","article-title":"Fludarabine, mitoxantrone, and dexamethasone:an effective new regimen for indolent lymphoma","volume":"14","author":"McLaughlin","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.009_bib34","first-page":"34","article-title":"NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease","volume":"17","author":"Hagemeister","year":"1990","journal-title":"Semin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:38Z","timestamp":1761870998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2152265020302378"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparison of the BEAM and MITO\/MEL Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma: An Analysis of Efficiency and Treatment-Related Toxicity","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}